Journal
EXPERT REVIEW OF VACCINES
Volume 11, Issue 9, Pages 1071-1086Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.12.87
Keywords
liposomes; malaria; polymeric particles; vaccine; viral vectors; virosomes; virus-like particles
Categories
Funding
- Ministerio de Ciencia e Innovacion
- University of the Basque Country UPV/EHU [UFI11/32]
- FEDER funds [SAF2007-66115]
- University of the Basque Country UPV/EHU
Ask authors/readers for more resources
Currently, a vaccine against malaria has not yet been licensed. Different approaches have been explored with different immune responses, but neither has fulfilled the criteria for being approved. The most advanced candidate, RTS,S, is undergoing Phase III studies and comprises virus-like particles, liposomes and immunostimulatory molecules. Other strategies are based on the use of polymeric particles, viral vectors or virosomes. Here, the authors have summarized the clinical advances that have been made in the field of Plasmodium falciparum to date, since it is the main causal agent of severe malaria. The best strategies to further develop a vaccine against malaria have also been discussed. In fact, an appropriate formulation should be immunogenic, safe and well tolerated, and as far as possible, avoid the use of needles and require a low number of immunizations. Moreover, issues such as storage, costs and so on, have to be taken into account.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available